Nugent Marc, Wang Jiafu, Lawrence Gary, Zurawski Tomas, Geoghegan Joan A, Dolly J Oliver
International Centre for Neurotherapeutics, Dublin City University , Glasnevin, Dublin 9, Ireland.
Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin , Dublin 2, Ireland.
Bioconjug Chem. 2017 Jun 21;28(6):1684-1692. doi: 10.1021/acs.bioconjchem.7b00157. Epub 2017 May 22.
Numerous naturally occurring toxins can perturb biological systems when they invade susceptible cells. Coupling of pertinent targeting ligands to the active domains of such proteins provides a strategy for directing these to particular cellular populations implicated in disease. A novel approach described herein involved fusion of one mutated immunoglobulin G (IgG) binding moiety of staphylococcal protein A to the SNARE protease and translocation domain of botulinum neurotoxin A (BoNT/A). This chimera could be monovalently coupled to IgG or via its Fc region to recombinant targeting ligands. The utility of the resulting conjugates is demonstrated by the delivery of a SNARE protease into a cell line expressing tropomyosin receptor kinase A (TrkA) through coupling to anti-TrkA IgG or a fusion of Fc and nerve-growth factor. Thus, this is a versitile and innovative technology for conjugating toxins to diverse ligands for retargeted cell delivery of potential therapeutics.
许多天然存在的毒素侵入易感细胞时会扰乱生物系统。将相关的靶向配体与这类蛋白质的活性结构域偶联,为将它们导向与疾病相关的特定细胞群体提供了一种策略。本文所述的一种新方法涉及将葡萄球菌蛋白A的一个突变免疫球蛋白G(IgG)结合部分与肉毒杆菌神经毒素A(BoNT/A)的SNARE蛋白酶和转运结构域融合。这种嵌合体可以单价形式偶联至IgG,或通过其Fc区域偶联至重组靶向配体。通过与抗TrkA IgG或Fc与神经生长因子的融合体偶联,将一种SNARE蛋白酶递送至表达原肌球蛋白受体激酶A(TrkA)的细胞系中,证明了所得缀合物的效用。因此,这是一种通用且创新的技术,可将毒素与多种配体偶联,用于将潜在治疗药物重新靶向递送至细胞。